Sila Realty Trust (SILA) Q3 2024 earnings summary

Executive summary

• Portfolio consists of 136 properties totaling 5.3M rentable sq. ft. in 65 markets, primarily in the southern U.S., with a focus on high-quality healthcare assets and a triple net lease structure; 95.5% leased as of September 30, 2024, with a weighted average lease term of 8.3 years.

• Listed on the NYSE in June 2024, following a one-for-four reverse stock split and reclassification of share classes, enhancing visibility and access to capital.

• Completed a $50M Dutch Auction tender offer, repurchasing 2.2M shares at $22.60 per share, and authorized a new $25M share repurchase program.

• Year-to-date, completed $164.1M in acquisitions and $17M in dispositions, including a $28.4M inpatient rehab facility in Arkansas and sale of two vacant GenesisCare properties for $15.5M.

• Continued execution of strategy to invest in medical outpatient, inpatient rehab, and specialty facilities, with a robust acquisition pipeline.

Financial highlights

• Q3 2024 net income was $11.9M ($0.21/share), down from $15M in Q3 2023, but up from $4.6M in Q2 2024; AFFO was $31.7M ($0.57/share), and rental revenue was $46.1M, down 5% year-over-year.

• Cash NOI for Q3 2024 was $40.8M, down from $44.2M in Q3 2023, with a margin of 88.5%.

• AFFO payout ratio was 70.7% in Q3 2024; distributions declared per share were $0.40 for Q3 and $1.60 annualized.

• Net debt to EBITDAre ratio was 3.5x; interest coverage ratio was 6.6x; net debt leverage ratio was 26.1%.

• Cash and liquidity at quarter-end totaled $528.6M, including $28.6M cash and $500M undrawn credit facility.

Outlook and guidance

• Management expects disciplined growth in 2025, driven by a strong acquisition pipeline focused on Sunbelt and outpatient medical assets.

• Board approved a change from monthly to quarterly distributions starting in 2025.

• Weighted average rent escalation remained at 2.2%, supporting stable cash flows.

• Management sees greater opportunity in acquisitions over share buybacks at current stock price.

• No material changes to risk factors or critical accounting estimates; liquidity expected to be sufficient for the next twelve months.